Iveta Nováková

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

Medicine, Pharmacology, Pharmacotherapy +6

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 668 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +4

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex^®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Alena Novotná, Jan Mareš, S. Ratcliffe et al. · European Journal of Neurology · 2011 · 464 citations

Medicine, Neurology, Pharmacology +17

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

Richard Langford, Jan Mareš, Alena Novotná et al. · Journal of Neurology · 2012 · 297 citations

Medicine, Pharmacology, Pharmacotherapy +16

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

Christine Collin, Edvard Ehler, G Waberzinek et al. · Neurological Research · 2010 · 278 citations

Pharmacy, Neurology, Pharmacotherapy +16